Abstract
<h3>Introduction</h3> Sodium glucose co-transporter 2 (SGLT2) inhibitors have been reported to benefit liver functions in patients with type 2 diabetes (T2D) with non-alcoholic fatty liver disease (NAFLD). The aim of...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have